# Proof-of-concept, Open-label Study in Patients With Early Alzheimer's Disease

> **NCT05161715** · PHASE2 · COMPLETED · sponsor: **NewAmsterdam Pharma** · enrollment: 13 (actual)

## Conditions studied

- Early Alzheimer's Disease

## Interventions

- **DRUG:** Obicetrapib

## Key facts

- **NCT ID:** NCT05161715
- **Lead sponsor:** NewAmsterdam Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-12
- **Primary completion:** 2023-05-09
- **Final completion:** 2023-06-01
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2025-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05161715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05161715, "Proof-of-concept, Open-label Study in Patients With Early Alzheimer's Disease". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05161715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*